Family Financial Disclosure Form for COVID-19 Injections

Written by prepareforchange.net on March 18, 2021. Posted in Current News

Catherine Austin Fitts , president of Solari, Inc., publisher of the Solari Report, and managing member of Solari Investment Advisory Services, LLC., has created a Family Financial Disclosure Form for COVID-19 Injections — also known as the “Sane Person’s Guidebook.” Below we have reposted the form. We will include a link to the website for your convenience at the end of the post.

Introduction

The goal of this Family Financial Form is to ensure that an adverse event or death of one family member does not translate into long-lived or permanent financial destruction for the entire family.

This form was created to assist families to communicate regarding and to prepare for the family-wide financial impact of adverse events, if any, resulting from a Covid-19 injection. Examples of adverse events from Covid-19 injections include Covid-19 infection; anaphylaxis; neurological disorders; autoimmune disorders; other long-term chronic diseases; blindness and deafness; infertility, fetal damage, miscarriage, and stillbirth; and death (see Table 1 for examples of each).

Traditionally, informed consent forms for vaccination do not provide disclosure or statistics related to financial costs of possible injury, disability, or death, nor do they discuss the impact on family time, resources, health, and wealth—impacts that may include reduced career potential, divorce, and effects on siblings’ education and future plans.

Consequently, it is essential that prior to receiving a Covid-19 injection, parents and family members with financial responsibility for children and spouses not only perform thorough due diligence—providing adequate disclosures to their families regarding the potential costs to family members of adverse events or death—but also take steps to protect themselves and family members from the material adverse financial consequences of an adverse event or death.

What Are the Covid-19 Injections?

The leading Covid-19 injections currently in use in the U.S. and other OECD countries are experimental messenger RNA (mRNA) injections developed by Pfizer (with German partner BioNTech) and by biotechnology company Moderna (in partnership with the National Institute of Allergy and Infectious Diseases). The two experimental products are being distributed through emergency use authorizations (called “conditional marketing authorization” in the EU and “provisional approval” in Australia) granted following abbreviated clinical trials and without long-term safety testing. As yet, neither injection has received full approval or licensure from the FDA or any other national regulatory agency.

Though marketed as “vaccinations,” the Covid-19 mRNA injections are experimental gene therapy. Vaccine developers openly describe the never-before-authorized mRNA approach as a means of “programming a person’s cells”¹ or, using Moderna’s terminology, deploying new “software.”² In prior research, mRNA injections have displayed an intrinsic inflammatory component that has made it difficult to establish an “acceptable” risk/benefit profile.³

The mRNA approach requires an in-built “gene delivery system” (also called a “carrier system”) to deliver the synthetic mRNA into the cells’ cytoplasm before the mRNA breaks down. The Pfizer and Moderna Covid-19 injections use lipid nanoparticles (LNPs) for this purpose; the LNPs not only shield the mRNA and promote cellular uptake but also function as adjuvants, “revving up” the immune system. Pfizer’s and Moderna’s LNPs are coated with polyethylene glycol (PEG), a synthetic, nondegradable, and controversial polymer associated with adverse immune responses.

Moderna acknowledges that its LNPs “could lead to significant adverse events.”⁴ The FDA has identified PEG as the possible culprit responsible for anaphylactic reactions to the Covid-19 injections.⁵

In late February, the FDA authorized a third Covid-19 injection for emergency use in the U.S., manufactured by Johnson & Johnson’s Belgium-based pharmaceutical subsidiary, Janssen. J&J’s injection is an “adenovirus-vectored” vaccine that, like the mRNA injections, is intended to “trick” the cells into making coronavirus spike protein. The injection uses a genetically modified live common cold virus as a Trojan horse to “shuttle” spike protein DNA (genetic instructions) into human cells. In late 2019, the FDA approved an adenovirus-vectored Ebola injection, and the technology has also been featured in experimental—and problematic—Zika and HIV injections.⁶

The J&J Covid-19 injection is the first adenovirus-vectored injection to be authorized (on an emergency basis) for general population use.⁷

In Europe, the EU has granted conditional marketing authorization to a different adenovirus-vectored Covid-19 injection—using an adenovirus that usually infects chimpanzees—developed by AstraZeneca and Oxford. AstraZeneca called several time-outs during its Covid-19 vaccine clinical trials because trial participants developed transverse myelitis, a condition that damages the insulating material around nerves⁸ and is associated with pain, muscle weakness, paralysis, and bowel and bladder problems; two-thirds of the individuals who experience it remain permanently disabled.

Dozens of other Covid-19 injections are under development, including RNA-based, DNA-based, and viral vector injections as well as injections using other technologies.

The World Health Organization (WHO) has granted emergency authorization to both the Pfizer and AstraZeneca Covid-19 injections, opening the door for the injections to begin rolling out in poorer countries.

Adverse Event Reporting

As these Covid-19 injections are new, adverse event reporting is still in its early stages. However, compilations of news accounts⁹ and reports submitted to national databases such as the Vaccine Adverse Event Reporting System (VAERS) in the U.S.^10 11 already provide representative information about the Covid-19 injections’ potential health impact. See Table 2 for a list of selected public databases that make reports of adverse events available to the public and/or are collecting reports of injuries and deaths following Covid-19 injection.

See more here: prepareforchange.net

Please Donate Below To Support Our Ongoing Work To Expose The Lies About COVID19

PRINCIPIA SCIENTIFIC INTERNATIONAL, legally registered in the UK as a company incorporated for charitable purposes. Head Office: 27 Old Gloucester Street, London WC1N 3AX. 

Trackback from your site.